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Abstract
Increased interest in development of combined gene therapy emerges from results of recent clinical trials that indicate
good safety yet unexpected low efficacy of ‘‘single-gene’’ administration. Multiple studies showed that vascular endothelial
growth factor 165 aminoacid form (VEGF165) and hepatocyte growth factor (HGF) can be used for induction of
angiogenesis in ischemic myocardium and skeletal muscle. Gene transfer system composed of a novel cytomegalovirus-
based (CMV) plasmid vector and codon-optimized human VEGF165 and HGF genes combined with intramuscular low-
voltage electroporation was developed and tested in vitro and in vivo. Studies in HEK293T cell culture, murine skeletal
muscle explants and ELISA of tissue homogenates showed efficacy of constructed plasmids. Functional activity of
angiogenic proteins secreted by HEK293T after transfection by induction of tube formation in human umbilical vein
endothelial cell (HUVEC) culture. HUVEC cells were used for in vitro experiments to assay the putative signaling pathways to
be responsible for combined administration effect one of which could be the ERK1/2 pathway. In vivo tests of VEGF165 and
HGF genes co-transfer were conceived in mouse model of hind limb ischemia. Intramuscular administration of plasmid
encoding either VEGF165 or HGF gene resulted in increased perfusion compared to empty vector administration. Mice
injected with a mixture of two plasmids (VEGF165+HGF) showed significant increase in perfusion compared to single
plasmid injection. These findings were supported by increased CD31+ capillary and SMA+ vessel density in animals that
received combined VEGF165 and HGF gene therapy compared to single gene therapy. Results of the study suggest that co-
transfer of VEGF and HGF genes renders a robust angiogenic effect in ischemic skeletal muscle and may present interest as a
potential therapeutic combination for treatment of ischemic disorders.
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Introduction
Therapeutic angiogenesis using plasmid vectors carrying growth
factor gene is a broadly studied approach which has already
entered clinical trials and remained an important field of
translation research in recent decades. For example angiogenic
potential of plasmids with VEGF, HGF and basic fibroblast
growth factor has been shown previously [1–3]. Feasibility and
safety of plasmid-mediated stimulation of angiogenesis makes it a
very attractive choice for wide clinical application yet obtained
data indicates that use of single angiogenic growth factor may be
insufficient to render long-term positive effect in patients with
ischemic disorders. Double-blind, placebo-controlled clinical trials
of plasmid-based gene therapy in patients with peripheral artery
disease showed its safety and moderate efficacy which is definitely
below expectations [4,5]. These results raise the problem of new
approaches to increase beneficial impact of therapeutic angiogen-
esis questioning (1) factor(s) chosen for induction of angiogenesis,
(2) vectors and their administration routes and (3) possibility to
combine several genes.
Human studies showed safety of local administration of plasmid
DNA [6,7], however, in most cases authors reported extremely low
transfection efficiency [8,9]. The latter is a significant obstacle for
clinical implication which can be partially surmounted by use of
different additional methods – electroporation, ultrasound-medi-
ated gene transfer, polymer protection etc [10]. Another possible
solution is development of novel effective and safe plasmid vectors
with higher gene expression capacity which upon delivery would
induce robust therapeutic factor production. Several plasmid
systems have been developed and tested for animal and human use
[11]. In present study we constructed and used a novel plasmid
vector which comprises CMV immediate early promoter and
some other commonly used regulatory elements combined to
increase protein yield.
Finally it is possible to enhance angiogenic response using gene
therapy with physiologically additive combinations of factors.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38776Published animal studies report increase of efficacy after gene
therapy with pairs of VEGF/angiopoietin-1 [12], platelet-derived
growth factor BB/fibroblast growth factor-2 [13] etc. Our
previous experience in this field shows that delivery of VEGF165
and urokinase genes is an effective way to induce angiogenesis in
ischemic skeletal muscle [14].
Among other growth factors a pair of VEGF and HGF is a
potential candidate for therapeutic application. Both proteins are
known to show morphogenic, mytogenic and antiapoptotic
properties which are crucial for their regenerative potential [15–
17]. Regulation of expression and mutual effects of VEGF and
HGF has been thoroughly studied by many groups [18,19] to
identify possible basis for vivid in vitro findings of increased
angiogenic response induced by combination of these two factors
in cell culture and non-ischemic animal models of angiogenesis
[20,21]. Primarily angiogenic properties of HGF were attributed
to its stimulating paracrine effect on VEGF production by
endothelium. Further Van Belle et al. suggested that HGF effect
was related to induction of VEGF secretion by smooth muscle cells
[21]. However, later works clearly demonstrated that HGF and
VEGF have independent effects [22] and distinct signaling
pathways which mediate their activity via two tyrosine-kinase
receptors – c-met and VEGFR2 respectively.
Basing on these findings we hypothesized that combined
transfer of VEGF and HGF genes to ischemic tissue could be a
potent way to induce revascularization and restore blood flow. To
demonstrate that we used a novel highly effective plasmid vector
pC4W previously produced and described by our group [23] and
intramuscular low-voltage electroporation to enhance gene deliv-
ery. We also performed codon optimization of chosen genes to
increase their expression after plasmid transfection.
Materials and Methods
Ethics statement
All animal experiments carried out for the study were conducted
in accordance with Institute of Experimental Cardiology guide-
lines. Animal procedures were approved by the Ethics Board of
Institutional Animal Care and Use committee of Cardiology
Research Complex (permit number 385.06.2009).
Reagents and antibodies
Cell culture reagents. Dulbecco’s modified Eagle medium
(DMEM), M199 medium with Earle’s salt, 100x antibiotic/
antimycotic solution were purchased from Gibco, fetal bovine
serum was purchased from HyClone. Growth-factor reduced
Figure 1. VEGF165 and HGF contents in condition medium collected from HEK293T after transfection with pcDNA3- or pC4W-
based constructs with unoptimized/optimized cDNA sequence. (A) Human VEGF165 and HGF were assayed in conditioned medium
collected 48h after transfection of HEK293T by pC4W or pcDNA3-based vectors. (B) and (C) – corresponding western blot radiograms of same
medium samples after staining with antibodies against VEGF165 or HGF.
doi:10.1371/journal.pone.0038776.g001
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human VEGF165 (Cat#354107) and HGF (Cat#354103) were
purchased from BD Biosciences.
Plasmid purification. EndoFree plasmid Giga kit
(Cat#12391) was purchased from Qiagen.
Elisa kits. human QuantikineH VEGF165 (DVE00) and
HGF (DHG00) kits were purchased from R&D Systems.
Antibodies. mouse anti human VEGF165 monoclonal anti-
bodies (Cat#MAB3045), mouse anti human HGF monoclonal
antibodies (Cat#MAB294) were purchased from R&D Systems;
Pharmingen ratantimousePECAM(CD31)monoclonalantibodies
(Cat#550274) were purchased from BD Biosciences. FITC-labeled
mouse polyclonal anti smooth muscle antibodies (Cat#F3777) were
purchased from Sigma-Aldrich; AlexaFluorH594-conjugated don-
key anti rat secondary antibodies (A21209) were purchased from
Invitrogen; western blotting HRP-conjugated goat anti-mouse
secondary antibodies (Cat#115-035-174) were purchased from
Jackson Immunoresearch.
Figure 2. VEGF and HGF produced by transfected HEK293T cells induce distinct tubular structures formation in the HUVEC cell
culture. (A) Tube formation in the HUVEC culture after incubation with conditioned media collected from transfected HEK293T cells or with positive
control substance (100 ng/ml rhVEGF or rhHGF); 100x magnification, phase contrast. (B) Dose-response curves are obtained from wells with 25 ng/
ml, 50 ng/ml or 100 ng/ml of recombinant human VEGF or HGF. Data of 3 serial experiments is presented. (C) Mean tube length (mm) and branching
point number after HUVEC incubation with experimental conditioned media or positive control. For detailed data see Table 1.
doi:10.1371/journal.pone.0038776.g002
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was purchased from Sigma-Aldrich; 1x Quick Start Bradford Dye
Reagent was purchased from Bio-Rad (Cat#500-0205);
Cell lines
Human embryonic kidney (HEK) 293T cells were obtained
from ATCC; human umbilical vein endothelial cells (HUVEC)
were kindly provided by prof. A.V. Mazurov DSc from
Laboratory of cell adhesion of Institute of Experimental Cardiol-
ogy [24].
Animals
Eight-week old C57BL/6 male mice were used for hind limb
ischemia experiments, ex vivo detection of transgene expression and
electrotransfer efficacy evaluation with b-gal reporter plasmid. All
animals received standard food and water ratios. Surgical
manipulations and euthanasia protocols were designed in accor-
dance to Institute and National regulations.
Plasmid construction and purification
Mammalian expression vector pC4W as well as codon-
optimized human VEGF165 and HGF genes have been described
earlier [23]. Unmodified and codon-optimized versions of each
gene were subcloned into pcDNA3 (Invitrogen) and pC4W
expression vectors for comparison. Reporter plasmid pC4W-
bGAL was generated by subcloning the E. Coli b-galactosidase
gene sequence into pC4W vector.
All plasmids were amplified in Escherichia coli (XL-blue) grown in
LB medium and purified using EndoFree Plasmid Giga Kit
(Qiagen). Standard LAL-test with aliquots of plasmids was
performed to assay pyrogenicity of each formulation. In all tested
samples endotoxin level did not exceed 10 EU per 1 mg of plasmid
DNA, which complies to manufacturer’s range and existing
Institute regulations for in vitro and animal tests.
Cell culture and Ca
2+/phosphate transfection
HEK293T cells were grown in complete DMEM. Transfection
was performed on a 6-well plate at 80–85% confluent in 2 ml of
complete DMEM. 0.2 ml of 2xHBS (50 mM HEPES, 280 mM
NaCl, 1.5 mM Na2HPO4, pH=7.1) was added by drops to 0.2 ml
of 0.3 M CaCl2 mixed with 2 mg of pDNA. Resulted mixture was
added to a 6-well plate followed by gentle swirling. Cells were
incubated overnight under standard conditions and medium was
replaced with condition medium (1% FBS DMEM). Aliquots of
condition medium were collected 48 hours later, mixed with
protease inhibitor cocktail and frozen at 270uC.
Tube formation assay
Early passage (,P4) HUVEC were plated on Matrigel-coated
24-well dish in a mixture of 20% FBS HUVEC medium and low-
serum conditioned medium from transfected HEK293T cells in
1:1 ratio to obtain final FBS concentration of 10% (total volume
200 ml). Negative control cells were treated with a mock mixture of
20% FBS HUVEC medium and conditioned medium from empty
pC4W-transfected HEK293T. Positive control wells were treated
with 25, 50 or 100 ng/ml of rhVEGF165 or rhHGF added to
10% FBS HUVEC medium. After 16 hours of incubation under
standard conditions tube formation was evaluated in micropho-
tographs taken under 1006magnification in phase-contrast mode.
Tube length and branching points numbers were counted in
MetaMorph software in 5 random FOV taken from each plate
well and mean values for control substance or tested medium
sample were obtained. All samples were tested in duplicate within
every experiment and total of 3 serial runs were taken for final
evaluation.
Ex vivo analysis of VEGF and HGF production by
explanted muscle
Skeletal muscle explant culture experiments were performed in
accordance with protocol described by Jang and Kim [25].
Skeletal muscle disruption and human VEGF and HGF
detection by ELISA
Skeletal muscle samples from animals injected with phHGF,
phVEGF or their combination were harvested at day 3, 7 or 14
and used for transgene protein detection by human-specific ELISA
(QuantikineH, R&D Systems). Negative control animals received
empty vector injection. Briefly, animal was sacrificed and m. tibialis
anterior was excised and washed in 1x PBS and then placed to a
mortar pre-cooled on liquid nitrogen. After addition of 500 ml
protein extraction buffer (0.5 M NaCl, 20 mM Tris (pH 7.5),
1 mM EDTA and 1x protease inhibitor cocktail) muscle was
disrupted on liquid nitrogen with a pestle; pulverized sample was
collected to a tube and then thawed on water bath at 37uC. Debris
Table 1. Tube formation assay results after incubation of HUVEC with 25 ng/ml rhVEGF, rhHGF or their combination.
Tube length, mm p vs neg. control Branching points, n p vs neg. control
VEGF cond. medium 6.1660.6 0.03 32.463.1 0.009
HGF cond. medium 8.25760.2 0.01 34.163.2 0.002
rhVEGF, 100 ng/ml 7.0260.5 0.02 38.763.2 0.001
rhHGF, 100 ng/ml 8.5160.5 0.01 37.762.9 0.01
Negative control (10 % FBS) 3.2560.7 - 21.364.3 -
doi:10.1371/journal.pone.0038776.t001
Figure 3. Histochemical detection of b-galactosidase activity in
murine muscle. Representative images of X-Gal stained murine
skeletal muscle cross sections after (A) Routine intramuscular injection
of pC4W-bGAL plasmid (B) Injection followed by transcutaneous low-
voltage pulses 506magnification, phase contrast mode.
doi:10.1371/journal.pone.0038776.g003
Combined VEGF+HGF Gene Therapy for Limb Ischemia
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38776was removed by centrifugation (19000 g, 10 minutes) and cleared
sample was used for Bradford total protein assay and ELISA
detection of human growth factors. For total protein assay the
samples were diluted up to 20 fold using protein extraction buffer,
for ELISA up to 5 times in accordance to manufacturer’s protocol.
Figure 4. VEGF and HGF concentration in animal tissue after delivery of VEGF, HGF or VEGF+HGF to ischemic muscle. (A) and (B)–
ELISA of human VEGF or HGF in transfected murine muscle homogenate sample at days 3, 7 and 14 post injection of single plasmids or their
combinations. Data is presented as mean6SD after normalization of produced transgene quantity per mg of total protein. Mean of 3–4 samples
assayed by specific ELISA presented. * p,0.05 vs VEGF+HGF.
doi:10.1371/journal.pone.0038776.g004
Figure 5. VEGF and HGF secretion by explanted muscle after in vivo gene transfer. (A) ELISA of human VEGF in medium from muscle
explants prepared 2 days after 100 mg of pC4W-hVEGFopt plasmid or pC4W empty vector injection. (B) Analogous data for human HGF secretion
after pC4W-hHGFopt plasmid injection. (C) Human VEGF and HGF secretion by muscle explants after a mixture of 100 mg pC4W-hVEGFopt and
100 mg pC4W-hHGFopt plasmid injection. (D) Dynamic profile of human VEGF production by trasnfected muscle. Explants harvested at different time
points after VEGF plasmid injection were used to assay VEGF secretion.
doi:10.1371/journal.pone.0038776.g005
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38776Figure 6. Laser Doppler imaging of ischemic limb reperfusion after growth factor gene transfer. (A) Dynamics of hind limb perfusion in
experimental groups of mice that received pC4W empty vector, phVEGFopt (VEGF), phHGFopt (HGF) or combination of phVEGFopt and phHGFopt.
Group details presented in text. * – p,0.05 vs pC4W, ** – p,0.05 vs pC4W and sole plasmids. (B) Representative laser Doppler images of the hind
limb perfusion in experimental groups at the study endpoint (day 21).
doi:10.1371/journal.pone.0038776.g006
Figure 7. Histological analysis of necrosis in muscle samples from study group animals. (A) Representative images of muscle sections
from different study groups. 2006magnification, hematoxylin-eosin staining. (B) Mean necrosis area/total section area for study groups. *p,0.05 vs
pC4W; **p,0.05 vs VEGF or HGF.
doi:10.1371/journal.pone.0038776.g007
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We used manufacturer’s protocol (R&D Systems) for ELISA
detection of VEGF165 and HGF in medium samples and tissue
homogenates by corresponding QuantikineH kit.
Western blotting
Samples of culture medium were used for SDS-denaturing
electrophoresis in a polyacrilamide gel under non-reducing
conditions according to standard procedures. Separated proteins
were transferred to a PVDF membrane (Millipore) with subse-
quent staining by monoclonal mouse anti human antibodies
against VEGF165 or HGF overnight at 4uC and with secondary
polyclonal HRP-conjugated goat anti mouse IgG antibodies for
1 hour at room temperature. Two-component West Pico chemi-
luminescent substrate system (Pierce) was used for development of
secondary antibodies.
Mouse hind limb ischemia model and injection of
plasmid solutions
Mice were narcotized by intraperitoneal injection of 2.5%
avertin solution calculated by body mass. Unilateral induction of
hind limb ischemia was performed as previously described [26].
All surgical manipulations were carried out in aseptic conditions
under binocular microscope. Briefly, skin was incised along
midline of left hind limb hip and a. femoralis with its branches
was ligated distal to inguinal ligament and proximal to its popliteal
bifurcation. Vessel was excised between upper and lower ligatures
and after control of hemostasis skin was closed with 5–0 silk
sutures. After completion of surgery animals were put until full
recovery into a chamber on an ambient heated pad. After surgery
one of plasmid formulations was injected to m. tibialis anterior of
ischemic limb. Animals were randomized to receive 100 mg
pC4W-hVEGFopt (n=10) or 100 mg pC4W-hHGFopt (n=10).
Combined transfer group received a mixture of plasmids: 100 mg
pC4W-hHGFopt+100 mg pC4W-hVEGFopt (n=9). Negative
Figure 8. Histological analysis of murine ischemic skeletal muscle neovascularization. (A) Representative images of sections stained for
smooth muscle actin and CD31. (B) SMA+ and CD31+ vessel counts per field of view. *p,0.05 vs pC4W; **p,0.05 vs pC4W-VEGF or HGF.
doi:10.1371/journal.pone.0038776.g008
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All injected plasmids (including combined transfer) were diluted in
100 ml of sterile saline throughout all study groups. Injection was
followed by transcutaneous electric pulses as previously described
by Schertzer and Lynch [27] with a minor modification – we
omitted injection of hyalouronidase to muscle. For electric pulsing
Table 2. Capillary (CD31) and arteriole (SMA) density in muscle sections from different study groups.
SMA+ arteriolae
p vs control (Mann-
Whitney U) CD31+ capillaries p vs control (Student’s t)
Empty pC4W 1.3160.15 - 322.4644.9 -
VEGF 1.8660.19 0.03 364.2653.0 0.0001
HGF 1.7860.21 0.002 354.6625.0 0.002
VEGF+HGF 2.660.18 0.001 477.7675.6 0.0001
doi:10.1371/journal.pone.0038776.t002
Figure 9. VEGF and HGF cooperate to induce ERK1/2, but not Akt or P38-mediated intracellular signaling. (A–C) – HUVEC were
stimulated by 25 ng/ml of VEGF165, HGF or their combination (5 or 15 minutes). Cell lysates were analyzed using western blot with specific
antibodies against phosphorylated ERK1/2, Akt or P38 and normalized against b-actin or Akt to obtain densitometric data and corresponding graphs
(right column).
doi:10.1371/journal.pone.0038776.g009
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generator equipped with tweezer electrodes.
Laser Doppler perfusion measurement
Blood perfusion was assessed using a Moor LDI 2.0 system in
isoflurane-narcotized animals at 7-day intervals for 3 weeks.
Animals were placed to an induction chamber, narcotized by
isoflurane inhalation and then placed on an ambient heating pad
for 10 minutes under 1–2% isoflurane/oxygen inhalation for
stabilization of narcosis depth and blood pressure. Consequent
perfusion measurements on plantar surface of animal’s feet were
made and data variability was analyzed using Moor image review
software. Readings were taken until 3 subsequent runs with
minimal (,10%) deviation were obtained. To account for
variability among measurements, ambient light and temperature
fluctuations all raw perfusion units readings were normalized
against non-ischemic limb and expressed as relative perfusion per
cent.
Muscle harvest and histological analysis
At day 21 animals from test groups were sacrificed by lethal
isoflurane dose followed by cervical dislocation and ischemic m.
tibialis anterior was harvested and frozen in TissueTek medium.
Serial frozen sections (7 mm) were prepared and stained for tissue
analysis.
We used hematoxylin-eosin staining for tissue necrosis analysis.
Necrotic muscle span is expressed as percent to total section area.
Signs of muscle necrosis were loss of fiber morphology, cytoplasm
disruption, inflammatory cells infiltration and fibrosis.
For immunofluorescent analysis sections were formalin-fixed
and then incubated overnight with corresponding primary and –
after wash – secondary antibodies (2 h) and counterstained with
DAPI. Stained sections were mounted in aqeous-based medium
for subsequent microscopy.
Microphotographs of sections were taken under 2006 magni-
fication in 5 random FOV per section using Zeiss Axiovert 200 M
fluorescent microscope with Axiovision 3.1 software. Manual
vessel counts in microphotographs were made by two independent
persons in MetaMorph 7.1.0.0 software. Capillary density analysis
included manual counts of CD31-positive structures per FOV;
arteriolar counts were obtained as number of SMA(+) blood
vessels with clearly visible CD31(+) inner layer per FOV. Capillary
and arteriole counts per FOV were used to obtain mean values for
section, animal or group and were subject to subsequent statistical
assessment.
X-gal staining of tissue sections
Frozen section of muscle were formalin-fixed and stained for b-
galactosidase activity by incubating them for 24 hours in warm
PBS-based solution containing 5 mM potassium ferricyanide
crystalline; 5 mM potassium ferricyanide trihydrate; 2 mM MgCl2
and 1 mg/ml X-Gal (Sigma-Aldrich). Slides were incubated under
37uC overnight and then washed in PBS and mounted in aqueous-
based medium for further microscopy. Transfection efficacy was
expressed as ratio of b-galactosidase positive muscle fibers/total
fibers in section.
Statistical analysis
Data is expressed as mean 6 SD (SEM in some exceptions).
Statistical significance of difference between 2 groups was
determined using a Student’s t-test or Mann-Whitney rank sum
U-test depending on sample distribution profile analyzed by
Shapiro-Wilk test. Multiple groups were compared using appro-
priate statistical method with Bonferroni’s correction for critical
level of significance. Statsoft Statistica 6.0 was used for analyses of
study data.
Results
Plasmid constructs encoding codon-optimized human
VEGF165 and HGF genes
We have constructed a novel mammalian expression vector
pC4W. Briefly the expression cassette of pC4W consists of human
CMV immediate-early promoter/enhancer, rabbit beta-globin
intervening sequence-2, consensus translation initiation sequence,
woodchuck hepatitis virus posttranscriptional regulatory element
(WPRE), and bovine growth hormone and simian virus 40 early
polyadenylation signals.
To enhance the expression of VEGF and HGF genes we used
codon optimization strategy based on the genetic code redundan-
cy. Coding regions of human VEGF165 and HGF gene were
screened for the presence of codons occurring with the lowest
frequency in human open reading frames. Using conventional
genetic engineering and gene synthesis technologies, rare codons
were replaced by the most frequent codons encoding the same
amino acids, resulting in preservation of the amino-acid sequence
of each protein. Furthermore, two signals of mRNA polyadenyl-
ation AATAAA and two mRNA destabilizing signals ATTTA
[28] were excised from the human HGF coding region using same
technique.
Study of VEGF165 and HGF expression in cell culture
To assay expression activity of different plasmid constructs in
vitro we transfected them to HEK293T cells. Aliquots of condition
medium collected after transfection were assayed for human
VEGF165 or HGF contents by Western blotting and ELISA. As
shown in Fig. 1 (B, C) cells treated with pC4W-based constructs
produce more target protein compared to cells transfected with
pcDNA3-based constructs encoding the same gene. Furthermore,
application of plasmid constructs with optimized genes hVEGFopt
and hHGFopt resulted in higher protein production than after
transfection by plasmids encoding unmodified VEGF or HGF
sequences. Quantitative ELISA of conditioned media confirmed
that use of pC4W-based vectors with optimized cDNA sequences
resulted in highest VEGF or HGF production (Fig. 1, A).
According to this all further ex vivo and animal experiments were
carried out using plasmids with the highest protein yield in
HEK293T cell culture – pC4W-hVEGFopt and pC4W-
hHGFopt.
Secreted VEGF165 and HGF induce tube formation in
HUVEC culture
To evaluate angiogenic activity of VEGF and HGF produced
by HEK293T after transfection with pC4W-hVEGFopt and
pC4W-hHGFopt we collected medium containing secreted
proteins and transferred it to human umbilical vein endothelial
cells (HUVEC) on Matrigel-coated surface. Freshly isolated
HUVEC were plated in a mixture of double (20%) FBS HUVEC
medium and conditioned medium from transfected HEK293T
cells in 1:1 ratio. Tube formation after 12–14 hours of incubation
was evaluated by measuring mean tube length and branching
point (BP) number per field of view at 1006magnification.
As expected, HUVEC showed comparable angiogenic response
after treatment with 100 ng/ml of positive control proteins
(rhVEGF or rhHGF); for details see Table 1 and Fig. 2. In
HUVEC incubated with medium from VEGF- or HGF-express-
ing HEK293T mean tube length and BP counts were significantly
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control stimulations with VEGF and HGF.
Low-voltage electroporation enhances plasmid gene
transfer to murine skeletal muscle
To assay effect of low-voltage pulses on gene delivery after single
intramuscular injection of plasmid DNA we used pC4W-based b-
galactosidase expressing reporter construct. It was injected to m.
tibialis anterior and transcutaneous pulses were applied as described
[27]. Muscles were harvested 3 days later and frozen sections were
prepared and stained by X-Gal to detect b-galactosidase activity
(Fig. 3). b-galactosidase positive fibers percentage was 17.164.7%
after electroporation vs. 2.261.2% without electroporation
(p,0.001). Our data demonstrates that low-voltage pulses leads
to dramatic increase of b-galactosidase positive fibers number and,
thus, overall transfection efficacy.
Production of human VEGF165 and HGF by murine
skeletal muscle
Production of human growth factors in murine muscle after
gene transfer was detected by ELISA of tissue samples and
medium samples collected from muscle explant cultures. Homog-
enates were prepared from muscle samples taken at day 3, 7 and
14 post injection (pC4W-hVEGFopt, pC4WhHGFopt or their 1:1
mixture) and after centrifugation were assayed with a human-
specific kit (R&D Systems).
Significant amount of transgenic protein (normalized to total
protein amount) was detectable in samples taken at every time-
point we used yet declining tendency can be obviously seen in
presented data (Fig. 4 A, B). No cross-reactivity was found and
signal in negative control (empty vector injection) or cross-group
analyses was below limits of detection.
Muscle explants were prepared from m. tibialis anterior harvested
2 days after injection of plasmid DNA (VEGF, HGF or
combination). At days 3 and 7 after explantation medium samples
were collected for ELISA of human VEGF or HGF contents.
Single VEGF or HGF plasmid injection followed by low-voltage
electroporation resulted in increasing over time concentration of
human angiogenic factor in medium that contained skeletal
muscle explant (Fig. 5, A, B). Very little background signal was
detected in control explants injected with empty pC4W vector.
In our homogenate ELISA tests we found significant gene
expression timespan of at least 14 days after injection of single
plasmid or their mixture (Fig. 4). We also analyzed human VEGF
secretion by muscle explants form animals sacrificed at days 2, 7,
14 and 30 after VEGF plasmid injection. Human VEGF
production was maximum in samples taken at day 7 after injection
and then gradually decreased being still detectable in samples
taken at day 14 after phVEGF administration (Fig. 5, C) with
almost no signal at day 30 indicating gene expression fadeout
during week 3.
Expression of human VEGF and HGF after combined gene
transfer was assayed using both models. Mice were injected with a
mixture of 100 mg phVEGF and 100 mg phHGF plasmids and
after a period of time muscle samples were harvested and used for
ELISA or explanted in Matrigel. In explant culture of a muscle
harvested at day 2 after injection we found that amount of each
angiogenic factor after plasmid mixture administration was
comparable to values obtained after injection of sole plasmid
encoding the corresponding human gene (Fig. 5, D). Direct
ELISA of muscle homogenates taken at day 3 showed comparable
data yet in later terms (at day 7) we found a significant increment
in human growth factor contents in sole plasmid groups compared
to VEGF+HGF which still diminished by day 14 as total
production of transgenic factor declined (Fig 4).
Effect of human VEGF and HGF co-transfer in mouse hind
limb ischemia model
All animals had similar perfusion rates before and after
induction of ischemia and no significant deviation of baseline
values at day 0 were found within groups. After induction of
unilateral ischemia mice were distributed to experimental groups
and received one of the following pro-angiogenic gene therapy
treatments:
1) pC4W-hVEGFopt (100 mg in 100 ml of saline).
2) pC4W-hHGFopr (100 mg in 100 ml of saline).
3) mixture of pC4W-hVEGFopt and pC4W-hHGFopr
(100 mg each in total volume of 100 ml).
4) pC4W empty vector as negative control (100 mg in 100 mlo f
saline).
Limb perfusion measurements were performed at days 7, 14
and 21 after surgery and plasmid injection as described in
Materials and Methods. No significant necrotic changes were
observed in most animals throughout the study, yet in some
control mice amputations of toes were registered.
We found that single injection of 100 mg pC4W-hVEGFopt
(VEGF group) or pC4W-hHGFopt (HGF group) plasmids
followed by electroporation rendered significant and comparable
angiogenic effect by day 21 showing increase of perfusion
compared to the empty vector pC4W injection (Fig. 6). Relative
perfusion values in animals that were subjected to combined
(VEGF + HGF) gene transfer were higher than in any other group.
As for combined VEGF and HGF gene transfer we injected
200 mg of total plasmid DNA versus 100 mg for single gene
transfer, we also assessed the influence of plasmid DNA quantity
on angiogenic effect expressed as restoration of perfusion. For that
purpose we conducted additional animal test with double dose of
pC4W-hVEGFopt plasmid. By day 21 after surgery and plasmid
administration mice that received 200 mg of pC4W-hVEGFopt
plasmid showed perfusion rates similar to mice injected with
100 mg of the same plasmid (data not shown).
Histological analysis of skeletal muscle
At day 21 after surgery and plasmid administration animals
were sacrificed and frozen cross-sections of m. tibialis anterior were
prepared for further histological analysis.
Necrosis signs were especially prominent in sections of the
central portion of m. tibialis anterior. Disrupted tissue span expressed
as necrotic tissue area/total area section was significantly higher in
empty vector group than in any other experimental group
indicating severe ischemic damage to skeletal muscle. Ischemic
muscle disruption was drastically reduced in animals treated with
VEGF, HGF plasmid or their combination (Fig. 7).
CD31-positive (CD31+) capillaries and smooth muscle actin
positive (SMA+) vessels were counted after double immunfluor-
escent staining (Fig. 8) to provide morphological evidence of
endothelial proliferation and mature vessel formation after gene
transfer. CD31+ capillary density as well as SMA+ vessel number
increase was registered in animals injected with single VEGF or
HGF plasmid compared to empty vector group. In combined gene
transfer group (VEGF + HGF) we found significantly higher
capillary density and SMA+ vessel number compared to VEGF or
HGF groups (Table 2) indicating higher sprouting activity in
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angiogenic growth factors.
VEGF and HGF cooperatively stimulate ERK1/2
phosphorylation
To investigate which signalling pathways are activated by
combination of VEGF and HGF we analyzed phosphorylation of
several MAPKs (mitogen activated protein kinase) in HUVEC
stimulated by recombinant HGF, VEGF or both. VEGFR-2 and
c-met downstream cascades may have several cross-talk points and
using western blot with antibodies specific against phosphorylated
forms of ERK1/2 (extracellular-signal-regulated kinase 1/2), p38
kinase or Akt we found that treatment with VEGF and HGF
together resulted in greater phosphorylation of ERK1/2. In our
study we didn’t observe enhanced activation of Akt and p38 after
VEGF+HGF addition and found HGF to be a more potent
inductor of Akt and P38 (Fig. 9). As for single factor stimulation we
used 25 ng/ml of VEGF or HGF and for co-stimulation we used
amount of proteins to create 25 ng/ml of each factor (50 ng/ml
total protein) we also analyzed ERK1/2 activation in 50 ng/ml
VEGF or HGF. This test intended to show that increment in
ERK1/2 phosphorylation was not due to higher amount of
protein in cell medium. We didn’t find increase of ERK1/2
activation after doubling VEGF or HGF concentration and same
data was obtained for p38 and Akt. Effect over time curves showed
slight difference between VEGF and HGF property to activate
ERK1/2 yet stimulation by VEGF+HGF led to stable enhancing
effect during the period of stimulation.
Discussion
Limb ischemia is a great medico-social burden which along with
population ageing that correlates with decrease of body regener-
ative capacity [29] will emphasize this problem in the future and
drive new investigations in this field.
Completed and ongoing clinical trials focus on single growth
factor administration for induction of angiogenesis. Most of them
show moderate to low beneficial effect of angiogenic ‘‘monother-
apy’’ for peripheral artery disease after pDNA injection to
impaired tissue. Since the original successful attempt by J. Isner
[1] gene therapy of limb ischemia was a field of great promise, but
results of first placebo-controlled clinical trials became a real
disappointment for most specialists [30]. Clinical studies of
VEGF165 plasmid showed it safety but low efficacy in most cases
[4,31]. Recent trials with HGF showed its safety yet insignificant
beneficial effects in critical limb ischemia [32,33] and moderate
efficacy in Buerger’s disease [2]. Finally, recent failure of a phase
III trial of NV1FGF [34] became another proof that field of
therapeutic angiogenesis requires new possible ways to increase
efficacy and novel approaches for gene delivery. One of concepts
that is intensively studied in recent decade is to apply combined
gene therapy by several growth factors with independent targets/
receptors and pleiotropic beneficial properties. Thus, development
of in vivo applicable vectors is also a great point especially taking
into consideration that plasmid vectors are safe and feasible with
minimal immunogenicity (compared to viral particles) which
makes them an attractive object for implication in combined
transfer.
In our study we tested a new delivery tool – a plasmid vector
with high protein output and used a combination of two growth
factors – VEGF165 and HGF to augment angiogenesis in ischemic
skeletal muscle.
VEGF165 is a well-known growth factor and has become an
important object of biological and medical research due to its role
in angiogenesis, tumor growth and development. For deeper
insights into its biological properties one can be advised to pay
attention to a series of excellent reviews by N. Ferrara et al.
[17,35–37]. Therapeutic use of VEGF165 became a major object
for clinical implication yet many studies report mediocre to low
efficacy and significant dose-limiting side effects: tissue edema,
inflammatory response due to adhesion molecule upregulation etc.
The second of a pair – HGF is known to activate endothelial cells
migration, proliferation and tube formation although in contrast to
VEGF these effects are not limited to endothelial cells. HGF
induction is observed in injured skeletal muscle and myocardium
and in many tumors and tumor-derived cell lines along with its
receptor – c-met. Important feature of HGF for therapeutic
angiogenesis is its ability to induce significant angiogenic response
without increasing vascular permeability or inducing inflammatory
changes in the tissue [38].
In previous studies combination of HGF and VEGF165 has
been tested in endothelial cell cultures. In vitro application of
HGF+VEGF results in a more robust proliferative and chemo-
tactic response than each growth factor alone. More complicated
3D collagen models showed that only combination of VEGF and
HGF was capable of inducing signification tubulogenic response
and facilitate cell survival, yet neither VEGF nor HGF alone was
[20]. Studies by Min et al. showed that in HUVEC culture HGF
can inhibit VEGF-induced expression of adhesion molecules
ICAM-1 and VCAM-1 suppressing inflammatory response both in
cell culture and in animal hypersensitivity reaction model. This
effect was attributed to HGF ability to inhibit NF-kB pathway
activated by VEGFR2 downstream signaling [39]. These findings
show created a basis for further in vivo studies using rhHGF and
rhVEGF in rabbit ischemic limb and corneal angiogenesis assay to
support previous findings [21], but combination of VEGF165 and
HGF has never been tested in gene transfer studies.
In first part of our work we tested a novel plasmid vector and
evaluated its efficacy compared to conventional pcDNA3 vector
system. Novel pC4W vector consists of CMV promoter and a
number of additional regulatory elements which are combined to
obtain higher protein yield. In our cell culture tests we found
higher target protein contents after transfection with pC4W-based
plasmids compared to pcDNA3-based ones. We also showed
additional expression enhancement obtained by codon optimiza-
tion of angiogenic factor genes selected for our study. Using more
effective vectors combined with a safe enhancing technique (e.g.
electrotransfer we applied) may result in more successful angio-
genesis induction. It seems that there can be a ‘‘threshold’’
concentration/gradient of growth factor which is required to
induce cell proliferation and migration leading to formation of a
vessel or to promote survival of both – pre-existing and dividing
endothelial cells. Thus if transfected tissue generates higher
amount of therapeutic protein this can lead to better tissue
protection against ischemia preventing necrosis, fibrosis or
pathological proliferation. In our work we used explant model
and tissue homogenate ELISA to confirm human protein secretion
by transfected murine muscle. This allowed us to detect secreted
human transgene and to ensure that vector activity is sufficient to
provide significant amount of target proteins.
Regarding combined angiogenic factors gene transfer little is
known about administration of several plasmids in one ‘‘shot’’.
Our data indicates that in early terms (2–3 days after injection)
protein production after combined delivery is similar to single gene
transfer. However, ELISA tests of muscle homogenate samples
show that at approximately 1 week there is a significant difference
in production of a ‘‘couple’’ of factors by transfected muscle
compared to single factor delivery. Tissue VEGF and HGF
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combined plasmid injection. This finding that creates an image of
discrepancy at first glance makes increase in perfusion we observed
after VEGF+HGF treatment even more intriguing. It can point
out a possible case for biological amplification of effect as total
‘‘therapeutic protein’’ amount is constant yet perfusion is
enhanced. Thus, our data can indicate that chosen therapeutic
factors in lesser quantities can deliver greater benefit when acting
together over a period of time after delivery to ischemic tissue.
Regarding later time-points we found that by day 14 both proteins
are secreted in comparably low quantities and sole plasmid groups
have the same protein yield as combined transfer. Similar data was
obtained by Korpisalo et al [40] for adenoviral delivery of VEGF-
A and PDGF-B to ischemic muscle, yet very few observations are
made in regard to plasmid-mediated co-delivery of 2 therapeutic
proteins. Still while analyzing obtained data we should take into
consideration that direct tissue sample analysis reflects in situ
protein production and explant cultures are a great tool for long-
term detection of transgene (especially when its production
declines) due to protein accumulation in condition medium over
time.
We evaluated expression period of pC4W-based vector in
explants and tissue samples harvested at different time-points after
injection. Protein production was maximum in specimen taken at
days 3–7 with major decline in samples taken at day 14 reflecting
drastic fall of protein production. Plasmid vector activity
decrement after 2 weeks since administration to skeletal muscle
is attributed to plasmid DNA efflux and degradation resulting in
lower copy number and subsequent protein extinction. This
‘‘fading period’’ during the 2
nd week might be the most
appropriate time point for administration of a repeated injection
of plasmid DNA to support angiogenic response and factor
concentration.
In vivo tests were performed in mice with unilateral limb
ischemia. VEGF- and HGF-induced limb reperfusion after
plasmid injection has been reported and reproduced in many
works and has been translated to clinical trials. In our study
efficient stimulation of angiogenesis after injection of constructed
vectors to ischemic skeletal muscle was shown both by blood flow
increase and histological findings which included higher CD31+
and SMA+ vessel counts reflecting dense capillary network
formation and arteriogenic properties of both factors. Novel
finding in this experiment is increasing (up to 75%) perfusion after
injection of VEGF+HGF plasmids mixture. We found perfusion in
combined VEGF+HGF group to be the highest compared to
single plasmid or control. Laser Doppler data was supported by
higher capillary and arteriolar density found in combined transfer
group animals compared to sole HGF or VEGF groups.
Our in vitro tests in HUVEC cultures indicate that one of
putative pathways responsible for angiogenic effect amplification
could the ERK1/2 signaling cascade. In our studies we didn’t find
increase in Akt or p38 phosphorylation yet in all cases HGF was a
more potent inductor of studied pathways than VEGF165. Thus,
we can speculate that one of possible mechanisms for amplified
angiogenic response is ERK1/2-mediated increase of endothelium
proliferation. Most published data covers several possible mech-
anisms of interaction including thorough study of signaling cross-
talk yet comprehensive explanation is still elusive and will be the
subject of further studies.
Thus, to conclude, our data indicates that novel pC4W vector is
a highly effective and feasible plasmid for therapeutic gene delivery
to skeletal muscle. Ex vivo experiments showed that gene of interest
expression retains for at least 14 days after single administration of
pDNA. Further we also showed that angio- and arteriogenesis in
skeletal muscle can be successfully induced and augmented by
administration of combination of pC4W-based plasmids with
optimized cDNAs of VEGF165 and HGF.
Summarizing our data we can expect the combination of VEGF
and HGF to become one of candidates for future translational
research along with other candidate pairs: VEGF+angiopoietin-1,
VEGF+FGF e t c.
By the moment all published observations regarding use of
several growth factors gene transfer are limited to animal studies
due to safety reasons but after first pilot trials and accumulation of
safety and prospective data we can expect this approach to become
a ‘‘new level’’ technique in therapeutic angiogenesis. Translation
of this method to clinical practice may also require development of
next generation bicistronic vectors suitable for human use to
administer two genes in one plasmid but use of two separate
vectors for reach gene suggested in our study seems to have a great
advantage of equal expression of both therapeutic factors which
popular IRES-based bicistronic vectors lack after in vivo admin-
istration as they do in vitro.
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